Showing 5 posts of 5 posts found.


Merck’s colorectal cancer drug meets primary endpoint in Phase III study

April 25, 2016
Research and Development, Sales and Marketing Erbitux, Merck, Serono, cancer drugs, colorectal cancer, increased survival, oncology, phase 3, phase III

Merck (FWB: MRK) has announced that its Phase III clinical trial of Erbitux, in combination with Folfox, met its primary …

Merck KGaA pays out $17 billion for Sigma-Aldrich

September 22, 2014
Manufacturing and Production, Sales and Marketing Millipore, Serono, Sigma-Aldrich, buyout, marck kgaa, sigma aldrich

Merck KGaA has swooped in and bought US-based Sigma-Aldrich in a deal worth $17 billion (€13.1 billion). The acquisition will …

Erbitux image

Merck KGaA declines in Q2

August 7, 2013
Sales and Marketing Erbitux, Merck KGaA, Q2, Serono

Sales of cancer drug Erbitux dropped as Merck Serono’s revenues for the second quarter of 2013 dipped year-on-year, the firm …

Merck KGaA confirms leadership team appointments

June 20, 2012
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing EMD Serono, Merck KGaA, Serono

The subsidiary of Merck KGaA named EMD Serono has announced several appointments to its leadership team. The appointments include: Allene …

Merck KGaA sets out savings target as staff threaten to strike

May 15, 2012
Research and Development, Sales and Marketing Merck KGaA, R&D, Serono, cuts

Merck KGaA has outlined its plan to make €300 million in savings from its Serono drugs unit, with over half …

Latest content